Back |
home / stock / opnt / opnt message board
Subject | By | Source | When |
---|---|---|---|
Opiant Pharmaceuticals, Inc., formerly Lightlake Therapeutics, Inc., is | fl89808 | investorshub | 03/22/2017 10:35:20 AM |
Actual PE now 2.02 and EPS shown as $4.21/sh | fl89808 | investorshub | 03/22/2017 12:10:10 AM |
10Q OUT! EPS = $4.91 / SH | fl89808 | investorshub | 03/16/2017 4:29:17 PM |
NARCAN sales accelerating all across the US and | fl89808 | investorshub | 01/13/2017 4:48:10 PM |
Only 2 million shares available! Any good | fl89808 | investorshub | 01/13/2017 4:42:26 PM |
$OPNT PE<7 which is ridiculous. Stock could easily | fl89808 | investorshub | 01/02/2017 5:22:22 PM |
Large cap here ~ $OPNT ~ Possibly going | Penny Roger$ | investorshub | 03/02/2012 4:30:49 PM |
~ $OPNT ~ Earnings posted, pending or coming | Penny Roger$ | investorshub | 02/07/2012 12:05:14 PM |
OPNET Technologies, Inc. (OPNET) is a provider of | Penny Roger$ | investorshub | 02/07/2012 12:05:08 PM |
News, Short Squeeze, Breakout and More Instantly...
Opiant Pharmaceuticals Inc. Company Name:
OPNT Stock Symbol:
NASDAQ Market:
CFIUS clearance represents the final required regulatory approval to complete the proposed merger Completion remains subject to the approval of Opiant stockholders; a special stockholder meeting to approve the acquisition will be held on March 1, 2023 Indivior and Opiant c...
SANTA MONICA, Calif., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals Inc. (NASDAQ: OPNT) announced today the expiration of the waiting period under the United States (U.S.) Hart-Scott-Rodino Act of 1976, as amended (HSR Act), with respect to the previously announced agreement for Opiant...
FDA sets PDUFA date of May 22, 2023 SANTA MONICA, Calif., Jan. 19, 2023 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for...